Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

Singh, Dave; Papi, Alberto; Corradi, Massimo; Pavlišová, Ilona; Montagna, Isabella; Francisco, Cristina de Oliveira; Cohuet, Géraldine; Vezzoli, Stefano; Scuri, Mario; Vestbo, Jørgen

doi:10.1016/s0140-6736(16)31354-x

Cited by 384 publications

(381 citation statements)

References 32 publications

Supporting

Mentioning

331

Contrasting

Unclassified

Order By: Relevance

“…The administration of 3 active substances such as Bechlomethasone/formoterol FF / glycopirronium through a single special device represent an impressive attempt to bring different substances endowed of complimentary actions to the proper targets in order to get a pharmachodynamic synergy. The study "Trilogy" [133] seems to give a frank support to this hypothesis. The triple combination obtained a significant success against the comparative association (BDP/FF) under important points of view: trough FEV1, SGRQ, burden of exacerbations.…”

Section: Analysis Of Currently Available Inhalation Drugs In Copdmentioning

confidence: 88%

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD

Donner

Amaducci

Bacci

et al. 2018

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

Section: Analysis Of Currently Available Inhalation Drugs In Copdmentioning

confidence: 88%

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD

Donner

Amaducci

Bacci

et al. 2018

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

show abstract

“…Two randomized, 3-month studies showed clinically relevant improvements in lung function with UMEC plus FF/VI, compared with placebo plus FF/VI, in patients with moderate-to-very severe COPD (9). The TRILOGY study (14) showed that triple therapy compared with ICS/LABA had a modest benefit with a reduction in exacerbations and an improvement in health-related quality of life; however, this appeared to wane as the study continued.…”

Section: Safety Analysesmentioning

confidence: 99%

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

Lipson

Barnacle

Birk

et al. 2017

Am J Respir Crit Care Med

281

311

View full text Add to dashboard Cite

“…The studies TRILOGY (Single Inhaler Triple Therapy versus Inhaled Corticosteroid plus Long-acting β-Agonist Therapy for Chronic Obstructive Pulmonary Disease) and TRINITY (Single Inhaler Extrafine Triple Therapy versus Long-Acting Muscarinic Antagonist Therapy for Chronic Obstructive Pulmonary Disease) both showed a reduction of exacerbations with triple therapy compared to LABA/ICS [61,62]. There are no data yet on triple therapy versus LABA/LAMA, but it is expected that two large trials will publish data later this year.…”

Section: Combination Therapiesmentioning

confidence: 99%

Exacerbations of COPD

2018

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with β-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, longterm antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.

show abstract

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

Cited by 384 publications

References 32 publications

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD

Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

Exacerbations of COPD

Contact Info

Product

Resources

About